As a globally recognized leader in silicone-based technology for more than 60 years, Dow Silicones Corporation advances healthcare through material innovation and manufacturing investment to help solve the most pressing bio-pharma processing challenges today and enable single use systems faster adoption. Dow Silicones Corporation offers one of the most expansive lines of silicone-based, performance enhancing solutions to provide manufacturers with safe, reliable and innovative solutions.

Dow Silicones Corporation is engaged in a significant investment roadmap to ensure its customers have access to state-of-the-art solutions and services. These key investments will help expand Dow Silicones Corporation dedicated elastomer and extrusion manufacturing capacity, will provide a more comprehensive set of data (BPOG, endotoxins, bioburden, particulates) for the validation of its single-use components by customers as well as will help accelerate the implementation of its innovation portfolio. In addition to an incremental capacity expansion program, Dow Silicones will upgrade its Healthcare Industries Materials Site extrusion facility to meet ISO 7 standards. The upgraded cleanroom is anticipated to be fully operational by the end of Q1 2019.

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.